Abstract:Abstract Background: Emerging literature has identified key immune cell populations that appear to significantly impact immune activation or suppression in patients with cancer. We investigated candidate populations and their differential infiltration within tumors as estimated from mRNA co-expression levels of corresponding cellular markers. Methods: We utilized clinical and transcriptomic data from patients with melanoma, urothelial, ovarian, and pancreatic carcinomas enrolled in the Total Cancer Care Protocol (NCT03977402) to which patients provided a written informed consent. We analyzed mRNA co-expression levels of biomarkers defining stem-like tumor-infiltrating lymphocytes (TILs) (TCF7, IL7R, CXCR5, CD28, and CD27), tissue-resident memory (TRM) T cells (CD69 and CD103), early dysfunctional T cells (PD1+, CCR5+, TCF7+, TIM3-), late dysfunctional T cells (PD1+, CD38+, CD39+, CD101+, TIM3+), activated-potentially anti-tumor (APA) T cells (PD1+, CD27+, CD28+, CD137+, GITR+), and Butyrophilin 3 A (BTN3A) isoforms (BTN3A1, BTN3A2, BTN3A3). Mann-Whitney U or Kruskal-Wallis H tests were used to compare median gene expression signature scores between immunotherapy (IO) responders (> 2 years survival) and non-responders (< 2 years survival). Cox regression was used to assess 2-year survival outcomes following immunotherapy. Results: We found a significant difference in the estimated infiltration of APA T-cells in melanoma (P = 4.67 Χ10−12 and P = 5.80 Χ10−12) and in urothelial carcinoma (P = 1.86 Χ10−09 and P = 1.38 Χ10−09) as compared to ovarian and pancreatic tumors, respectively. There was less TRM T-cell infiltration in ovarian compared to melanoma (P = 2.23 Χ10−8), urothelial (P = 3.86 Χ10−28) and pancreatic (P = 7.85 Χ10−9). A similar trend was seen with stem-like T-cells, early dysfunctional T cells, and late dysfunctional T cells. Differences in the expression of BTN3A isoforms were less apparent between the different tumors, with a trend towards higher expression in melanoma. In melanoma, a higher density of stem-like TIL, TRM, early dysfunctional T cells, late dysfunctional T cells, activated-potentially anti-tumor T cells, and BTN3A isoforms were associated with improved survival (P = 0.0075, 0.00059, 0.013, 0.005, 0.0016 and 0.041, respectively). A higher density of stem-like TIL was associated with improved survival in the urothelial cohort (P = 0.028). TRM gene signature had the best AUCROC as a moderate predictor of survival in our melanoma cohort (AUROC = 0.65); Examining the 6 signatures in public datasets of IO treated melanoma patients, they were similarly predictive of survival (AUROC of 0.61 - 0.64). Conclusions: Our results support a higher infiltration of key cellular elements related to immune activation within immunogenic versus non-immunogenic tumors supporting a central role in anti-tumor immune response. Citation Format: Ahmad A. Tarhini, Islam Eljilany, Sam Coleman, Dale J. Hedges, Martin McCarter, John Carpten, Howard Colman, Abdul Rafeh Naqash, Igor Puzanov, Susanne Arnold, Michelle Churchman, Patrick Hwu, William S. Dalton, George J. Weiner, Aik Choon Tan, Jose R. Conejo-Garcia, Paulo C. Rodriguez. Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 71.

Abstract A146: Systematic Discovery of Immune Regulatory Mechanisms in Tumor Cells

Functional genomic landscape of T-cell mediated cytotoxicity.

A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Abstract 1600: Cancer Driver Screens Identifyregulators of Immune Checkpoint Blockade Therapy Response

Abstract 1575: The landscape of tumor intrinsic immune regulators revealed by genome-wide CRISPR immune screen integrated with comprehensive clinical data analysis

Abstract 5371: Multimodal CRISPR activation screens reveal new mechanisms to sensitize cancer cells to targeted T cell mediated elimination

Abstract A28: Investigation of Tumor-Cell-intrinsic Factors Regulating Immune Infiltration and Response to Immunotherapy in Pancreatic Cancer

Abstract 2486: Dissecting tumor-immune interaction in response and resistance to immune checkpoint blockade in metastatic melanoma

Abstract 3964: A cancer survival program against activated T cell attack

Abstract 2276: Spatiotemporal Analysis of Metastatic Melanoma Reveals Mechanisms of Resistance to Immune Checkpoint Blockade

Abstract 2944: A high-throughput screening system for identifying therapeutic targets in immuno-oncology

Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma

Abstract B039: Elucidating the tumor-driven mechanisms of resistance to immunotherapies in pancreatic cancer through in vivo CRISPR/Cas9 knockout screening

Abstract B077: Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response

Abstract 71: Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy

Abstract 1509: Identification of Immunotherapy Resistance Mechanisms Within Tumor Microenvironment in a Mouse Model of Oral Squamous Cell Carcinoma

Abstract A12: Identification of Resistance to Immune Checkpoint Blockade

Abstract 3779: Clonal Tracing Reveals Different Mechanisms of Resistance to Immune Checkpoint Blockade

CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity

Abstract C034: Genome-wide CRISPR screen identifies novel immunotherapeutic targets in pancreatic cancer

Abstract 7547: Enhancers as targets for improvements in immunotherapy